Increase in the Aging Female Population to Create Opportunities for the Global Postmenopausal Osteoporosis Drugs Market Through 2020, Reports Technavio
LONDON–(BUSINESS WIRE)–#Healthcare—Technavio
analysts forecast the global
postmenopausal osteoporosis drugs market to grow at a
CAGR of around 4% during the forecast period, according to their latest
report.
The research study covers the present scenario and growth prospects of
the global postmenopausal
osteoporosis drugs market for 2016-2020. The report also lists
antiresorptive medications and anabolic medications as the two major
segments by therapeutic class.
Technavio healthcare
and life sciences analysts highlight the following four factors
that are contributing to the growth of the global postmenopausal
osteoporosis drugs market:
- Increase in older population
- Growing prevalence of postmenopausal osteoporosis
- Expected launch of promising pipeline molecules
- High unmet medical needs
Increase in older population
According to Barath Palada, a lead analyst at Technavio for women’s
health, “Nearly 85% of menopausal women, usually in their
late 40s or early 50s, have symptoms such as hot flashes, vaginal
dryness, pain, night sweats, loss of libido, and mood changes.” It is
also estimated that 30% of all postmenopausal women develop osteoporosis
during their lifetime. The population aged 60 years and older is
expected to grow by over 56% from 2015 to reach 1.45 billion by 2030.
Thus, the increase in the aging female population increases the chances
of osteoporosis, contributing to the growth of the market.
Growing prevalence of postmenopausal osteoporosis
The average life expectancy for women is estimated to be around 73
years, which increases the risk of developing postmenopausal
osteoporosis. During menopause, the amount of estrogen in the body
declines, resulting in osteoporosis. According to the World Health
Organization (WHO), osteoporosis is second only to cardiovascular
disease as a global healthcare problem. It is estimated that 30% of all
the women in the postmenopausal stage have postmenopausal osteoporosis
in the US and Europe. Bone mineral density in postmenopausal women can
be maintained or increased using drugs, which reduces the risk of
vertebral fracture and non-vertebral fractures. Therefore, the
prevalence of postmenopausal osteoporosis will drive the global
postmenopausal osteoporosis drugs market.
Expected launch of promising pipeline molecules
The entry of new players is set to intensify competition in this market.
Some late-stage pipeline molecules that may be launched during the
forecast period are Tarsa Therapeutics’ TBRIA (NDA review); romosozumab
(Phase III), joint collaboration of Amgen and Astellas; Merck’
odanacatib (Phase III), and Radius Health’s abaloparatide (Phase III).
The introduction of these candidates is likely to boost the growth of
the market.
High unmet medical needs
Tolerability and the method of drug administration are important factors
influencing compliance with the treatment plan. Effective pharmacologic
options are available to prevent and treat osteoporosis, but few slow
down the rate of bone resorption or reverse the long-term loss of bone
mass.
These unmet medical needs, in terms of safety, efficacy, and compliance,
inspire researchers to develop drugs that increase bone density, replace
lost bone, and rebuild bone strength. “In order to gain a competitive
advantage, market players should develop cost-competitive drugs with
ease of administration to promote bone building effectively,” says
Barath.
Browse Related Reports:
-
Osteoporosis
Drugs Market in the APAC Region 2015-2019 -
Global
Hormone Replacement Therapy Market 2015-2019 -
Global
Postmenopausal Vaginal Atrophy Drugs Market 2016-2020
Purchase these three reports for the price of one by becoming a
Technavio subscriber. Subscribing to Technavio’s reports allows you to
download any three reports per month for the price of one. Contact enquiry@technavio.com
with your requirements and a link to our subscription platform.
About Technavio
Technavio
is a leading global technology research and advisory company. The
company develops over 2000 pieces of research every year, covering more
than 500 technologies across 80 countries. Technavio has about 300
analysts globally who specialize in customized consulting and business
research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research
techniques to ascertain the size and vendor landscape in a range of
markets. Analysts obtain information using a combination of bottom-up
and top-down approaches, besides using in-house market modeling tools
and proprietary databases. They corroborate this data with the data
obtained from various market participants and stakeholders across the
value chain, including vendors, service providers, distributors,
re-sellers, and end-users.
If you are interested in more information, please contact our media team
at media@technavio.com.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
